NASDAQ:EDSA Edesa Biotech Q2 2026 Earnings Report $7.50 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$7.44 -0.06 (-0.80%) As of 07/2/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Edesa Biotech EPS ResultsActual EPS-$0.49Consensus EPS -$0.24Beat/MissMissed by -$0.25One Year Ago EPSN/AEdesa Biotech Revenue ResultsActual RevenueN/AExpected Revenue$0.05 millionBeat/MissN/AYoY Revenue GrowthN/AEdesa Biotech Announcement DetailsQuarterQ2 2026Date5/14/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsEdesa Biotech's next earnings date is estimated for Friday, August 14, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Edesa Biotech Earnings HeadlinesEDSA: Positive Exploratory Data in Patients with AKIJuly 2 at 8:10 PM | msn.comWall Street Zen Upgrades Edesa Biotech (NASDAQ:EDSA) to "Sell"June 27, 2026 | americanbankingnews.comSell Tesla, Buy the New King of FSD CarsIn 2023, Marc Chaikin's system flagged an automotive stock as bearish - and it fell 35% shortly after. Today, that same stock has earned a 'Very Bullish' rating after forming a major partnership with Nvidia to power AI-driven autonomous vehicles. This barely-known company was selected to handle the complex job of getting Nvidia's self-driving AI safely inside vehicles - positioning it at the center of a massive trend most investors are still missing through Tesla.July 4 at 1:00 AM | Chaikin Analytics (Ad)Edesa Biotech, Inc. Announces $3.5 Million PIPE Financing to Advance Clinical ProgramsJune 11, 2026 | quiverquant.comQEdesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused InvestorsJune 11, 2026 | globenewswire.comEdesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney InjuryJune 5, 2026 | financialpost.comFSee More Edesa Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Edesa Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Edesa Biotech and other key companies, straight to your email. Email Address About Edesa BiotechEdesa Biotech (NASDAQ:EDSA) is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa’s approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology. Among Edesa’s pipeline programs is a lead intranasal vaccine candidate targeting SARS-CoV-2, currently advancing through early-stage clinical trials. In parallel, the company is developing therapeutic vaccine constructs to address oncoviruses and tumor-associated antigens, as well as prophylactic immunizations for broader viral threats. Edesa’s integrated research facilities in Cambridge, Massachusetts support discovery, preclinical evaluation and process development in collaboration with academic and contract manufacturing partners. Headquartered in Cambridge, Edesa Biotech was founded by a team of immunologists and industry veterans. The company serves global markets through strategic alliances in North America, Europe and Asia. Under the leadership of CEO Steven M. Powell, PhD, Edesa is positioned to advance its pipeline toward late-stage clinical trials and to establish a differentiated platform for both infectious disease prevention and cancer immunotherapy.View Edesa Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 06/29 - 07/03Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive WeaponGeneral Mills Is a 5-Star Turnaround Play for Buy and Hold InvestorsCopper Stocks Are Getting a Bigger Spotlight as Gold’s Rally CracksNike Q4 Beat Masks Core Weakness as Analysts Cut Price TargetsIs the Memory Rally Still Alive After the Semiconductor Sell-Off?Hershey Stock May Be Near a Sweet Spot as Cocoa Pressure Eases Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
